Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05536960
Other study ID # NL80263.018.21
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 9, 2022
Est. completion date October 6, 2023

Study information

Verified date February 2024
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess whether vulnerable coronary plaques have more uptake of 68Ga-Dotatate than non-vulnerable plaques.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date October 6, 2023
Est. primary completion date October 6, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Aged 50 years and older - Underwent CCTA imaging within 78 weeks from the screening visit - Either CAD-RADS 4 or higher or 0/1 on CCTA. - Able to provide written informed consent Exclusion Criteria: - History of chronic kidney disease stage 3b - 5, defined as a CKD-EPI value of < 45 ml/min/1,73m2. - CVD events/revascularization in history - Malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator. - Chronic or recent (< 1 month) infections and/or clinical signs of acute infection. - History of auto-immune diseases. - Standard contra-indications to 68Ga-Dotatate PET, and CT based on physicians experience and current practices. - Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study. - Elevated liver enzymes (> 2 ULN of liver transaminases), acute liver failure or known liver disease.

Study Design


Intervention

Other:
68Ga-Dotatate PET/CT
One 68Ga-Dotatate PET/CT to determine uptake of tracer in the arterial wall.

Locations

Country Name City State
Netherlands Academic Medical Center Amsterdam

Sponsors (1)

Lead Sponsor Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in TBRmax Difference of target to background ratio (TBR)max in the coronary arteries between groups. 1 day
Secondary Correlation between TBRmax and FAI. Correlation of TBRmax with fat attenuation index, a specific CCTA parameter of vascular inflammation. 1 day
See also
  Status Clinical Trial Phase
Completed NCT03606330 - Systemic, Pancoronary and Local Coronary Vulnerability
Completed NCT05619042 - Detection of Coronary Artery Calcifications by Whole Blood Transcriptome Analyzed by Artificial InTelligence Algorithms
Recruiting NCT06182683 - Concurrent OCT and FFR-guided PCI in CAD N/A
Not yet recruiting NCT05071417 - Effect Of Semaglutide In Coronary Atheroma Plaque Phase 3
Recruiting NCT03894423 - Comprehensive Computed Tomography Guidance of Coronary Bypass Graft Surgery
Active, not recruiting NCT05567536 - Long Term Follow-up of Comparison of Clopidogrel vs. Aspirin Monotherapy After Drug-eluting Stent Implantation
Recruiting NCT06083337 - Vascular Inflammation ReDuction and Perivascular Fat Imaging by Computed Tomography N/A
Completed NCT04198896 - The Sakakibara Health Integrative Profile of Atherosclerotic-Carcinogenesis Hypothesis (SHIP-AC)
Completed NCT04835467 - First-In-Human Intracoronary OCT-FLIm In Patients Undergoing PCI N/A
Completed NCT04125992 - Distal vs. Forearm Radial Artery Access N/A
Completed NCT04826354 - Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease Phase 4